Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 3.111000
forwardPE 17.502146
debtToEquity 0.622000
earningsGrowth 1.668000
revenueGrowth 0.189000
grossMargins 0.672510
operatingMargins 0.157330
trailingEps 17.270000
forwardEps 23.300000

FDC's current ratio of 3.111, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as FDC has enough cash and current assets to handle its immediate liabilities comfortably.
FDC's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
FDC Limited's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that FDC Limited is expected to continue expanding its business and boosting its financial performance in the coming periods.
With a forward EPS greater than its trailing EPS, FDC is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


Analysts' buy bias for FDC signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to FDC, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.